| Literature DB >> 34344811 |
Sherif M El Desoky1, Mai Banakhar1, Khalid Khashoggi1, Zaher F Zaher1, Jameela A Kari1.
Abstract
OBJECTIVES: To review voiding dysfunction caused by 3 different etiologies; dysfunction voiding syndrome (DVS), neurogenic bladder secondary to spinal dysraphisim (NB), and valve bladder syndrome (VBS).Entities:
Keywords: Hinman’s syndrome; dysfunction voiding syndrome; neurogenic bladder; post valve bladder
Mesh:
Year: 2021 PMID: 34344811 PMCID: PMC9195553 DOI: 10.15537/smj.2021.42.8.20210327
Source DB: PubMed Journal: Saudi Med J ISSN: 0379-5284 Impact factor: 1.422
- Baseline patients’ demographic and disease characteristics (N=199).
| Baseline demographics | Total | DVS (n=75) | NB (n=64) | VBS (n=60) |
|---|---|---|---|---|
| n (%) | ||||
| Male | 134 (67.3) | 44 (58.6) | 30 (46.8) | 60 (100) |
|
| ||||
| Median (range) | 24 (192) | 48 (192) | 24 (168) | 9 (156) |
| Min (max) | 0.024 (192) | 0.024 (192) | 0.024 (168) | 0.024 (156) |
| Mean±SD | 43.9±49.6 | 60.1±6.32 | 43.5±6.21 | 24.1±4.37 |
|
| ||||
| Median (range) | 108 (252) | 120 (252) | 120 (238) | 88 (192) |
| Min (max) | 12 (264) | 12 (264) | 14 (252) | 12 (204) |
| Mean±SD | 114.7±65.2 | 124.9±8.5 | 122.1±7.7 | 94.0±6.7 |
| Follow-up duration by month median (range) | 72 (180) | 72.0 (156) | 72.0 (180) | 78.0 (144) |
|
| ||||
| Infancy up to 1 year | 91 (45.7) | 25 (33.3) | 30 (46.9) | 36 (60.0) |
| Toddler (1-5 years) | 52 (26.1) | 20 (26.7) | 17 (26.6) | 15 (25.0) |
| School age (5-16 years) | 56 (28.1) | 30 (40.0) | 17 (26.6) | 9 (15.0) |
|
| ||||
| Category 1 | 62 (31.2) | 25 (33.3) | 14 (21.9) | 23 (38.3) |
| Category 2 | 50 (25.1) | 15 (20.0) | 19 (29.7) | 16 (26.7) |
| Category 3 | 25 (12.6) | 11 (14.7) | 4 (6.3) | 10 (16.7) |
| Category 4 | 62 (31.2) | 24 (32.0) | 27 (42.2) | 11 (18.3) |
|
| ||||
| Negative | 112 (56.3) | 40 (53.3) | 33 (51.6) | 39 (65.0) |
| Positive | 87 (43.7) | 35 (46.7) | 31 (48.4) | 21 (35.0) |
|
| ||||
| Vesicostomy | 40 (20.1) | 16 (21.3) | 10 (15.6) | 14 (23.3) |
| Iliocystoplasty | 33 (16.5) | 14 (18.7) | 14 (21.9) | 5 (8.3) |
| Ureterostomy | 20 (10.0) | 9 (12.0) | 9 (14.1) | 2 (3.3) |
| Botox | 4 (2.0) | 1 (1.3) | 3 (4.7) | 0 (0.0) |
| Mitrofanoff/monti | 6 (3.0) | 3 (4.0) | 1 (1.6) | 2 (3.3) |
DVS: dysfunction voiding syndrome, NB: neurogenic bladder 2ry to spinal lesion, VBS: valve bladder syndrome, SD: standard deviation, Max: maximum, ESKD: end stage kidney disease, Botox: botulinum toxin injection into the bladder wall, Mitrofanoff: appendicovesicostomy, Monti: ileovesicostomy. Category 1: 62 children who did not need CIC or surgery, Category 2: 50 children who needed CIC but did not need surgery, Category 3: 25 children who have surgery but they did not need CIC. Category 4: 62 children who did need both CIC and surgery, CIC: clean intermittent catheterization
Figure 1- Comparison between age at presentation and initial and last estimated glomerular filtration rate test.
- Baseline clinical data of the 3 studied groups (N=199).
| Baseline clinical data | Total | DVS (n=75) | NB (n=64) | VBS (n=60) | |
|---|---|---|---|---|---|
| n (%) | |||||
|
| |||||
| Median (range) | 39.61 (135.4) | 45.15 (134.3) | 66.2 (134.3) | 23.1 (106.3) | |
| Min (max) | 3.2 (138.6) | 3.6 (129.7) | 4.3 (138.6) | 3.2 (109.5) | 0.001 |
| Mean±SD | 50.1±2.77 | 49.8±36.9 | 66.2±44.04 | 33.1±27.9 | |
|
| |||||
| Median (range) | 59.97 (137.3) | 55.0 (136.0) | 90.8 (136.7) | 37.7 (135.6) | |
| Min (max) | 3.1 (140.4) | 4.2 (140.2) | 3.7 (140.4) | 3.1 (138.7) | 0.000 |
| Mean±SD | 66.4±3.3 | 65.1±46.1 | 84.9±46.1 | 48.2±40.6 | |
| Comparison median initial eGFR: last eGFR, | <0.001 | <0.001 | 0.002 | 0.021 | |
|
| |||||
| Negative | 38 (19.1) | 8 (10.7) | 21 (32.8) | 9 (15.0) | |
| Positive | 161 (80.9) | 67 (89.3) | 43 (67.2) | 51 (85) | 0.002 |
| Unilateral | 49 (30.4) | 14 (20.9) | 22 (51.2) | 13 (25.5) | |
| Bilateral | 112 (69.6) | 53 (79.1) | 21 (48.8) | 38 (74.5) | |
|
| |||||
| Negative | 105 (52.8) | 34 (45.2) | 46 (71.9) | 25 (41.7) | |
| Positive | 94 (47.2) | 41 (54.7) | 18 (28.1) | 35 (58.3) | 0.618 |
| Unilateral | 79 (84.0) | 33 (80.5) | 15 (83.3) | 31 (88.6) | |
| Bilateral | 15 (16.0) | 8 (19.5) | 3 (16.7) | 4 (11.4) | |
|
| |||||
| Negative | 37 (38.1) | 18 (47.4) | 11 (28.9) | 8 (38.1) | |
| Positive | 60 (61.9) | 20 (52.6) | 27 (71.1) | 13 (61.9) | 0.657 |
| Unilateral renal scars | 34 (56.7) | 10 (50.0) | 17 (63.0) | 7 (53.8) | |
| Bilateral renal scars | 26 (43.3) | 10 (50.0) | 10 (37.0) | 6 (46.2) | |
| Obstruction on DTPA/MAG3, n=144 | 65 (45.1) | 20 (35.1) | 22 (48.9) | 23 (54.8) | 0.125 |
| CIC | 113 (56.8) | 40 (53.3) | 46 (71.9) | 27 (45.0) | |
| Oxybutynin | 123 (61.8) | 48 (64.0) | 48 (75.0) | 27 (45.0) | |
|
| |||||
| Pyelonephritis | 102 (37.2) | 44 (58.7) | 33 (51.6) | 25 (41.7) | 0.145 |
| Hypertension | 42 (15.3) | 24 (32.0) | 10 (15.6) | 8 (13.3) | 0.013 |
| Proteinuria | 24 (8.8) | 13 (17.3) | 1 (1.6) | 10 (16.7) | 0.007 |
| Hematuria | 5 (1.9) | 5 (6.7) | 0 (0) | 0 (0) | 0.012 |
| Progressive CKD | 61 (22.2) | 22 (29.3) | 17 (26.6) | 22 (36.7) | 0.452 |
| End Stage CKD | 40 (14.6) | 14 (18.7) | 9 (14.1) | 17 (28.3) | 0.132 |
| RRT | 23 (11.5) | 11 (14.6) | 4 (6.25) | 8 (13.3) | |
| Non | 176 (88.4) | 64 (85.3) | 61 (95.3) | 52 (86.7) | |
| Hemodialysis | 11 (5.5) | 6 (8.0) | 1 (1.6) | 4 (6.7) | |
| Peritoneal | 11 (5.5) | 5 (6.7) | 1 (1.6) | 4 (6.7) | |
| Transplantation | 1 (0.5) | 0 (0.0) | 1 (1.6) | 0 (0.0) | |
|
| |||||
| Mortality secondary to ESKD | 8 (4.02) | 4 (5.3) | 4 (6.2) | 0 (0.0) | |
Proteinuria ≥300 mg/L. Hematuria >10 HPF. Hypertension >95th percentile for age, gender, and height; CKD, worsening eGFR <60 ml/min/1.73 m[2]; end stage kidney disease, eGFR <15 ml/min/1.73 m2. DVS: dysfunction voiding syndrome, NB: neurogenic bladder due to spinal dysraphisim, VBS: valve bladder syndrome, SD: standard deviation, Max: maximum, eGFR: estimated glomerular filtration rate, RRT: renal replacement therapy, VUR: vesico-ureteral reflux, DMSA: di-mercapto-succinic acid, DTPA: diethylenetriamine penta-acetic acid, MAG3: technetium 99 mercapto-acetyl-triglycine scan, CIC: clean intermittent catheterization, CKD: chronic kidney disease
Figure 2- A) Comparison between the median of estimated glomerular filtration rate test (eGFR) for the surgical and non-surgical patient’s group. B) Comparison between the initial and last follow up median eGFR with regards to different management. Category 1: 62 children who did not need clean intermittent catheterization (CIC) or surgery, Category 2: 50 children who needed CIC but did not need surgery, Category 3: 25 children who have surgery but they did not need CIC, Category 4: 62 children who did need both CIC and surgery. *significant value (p<0.05).
Figure 3- Comparison of different variables depends to the last follow up estimated glomerular filtration rate test.